Shares of Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) spiked to a two-year high of $25 after the company reported that its lead candidate, omadacycline, met FDA primary and secondary endpoints and EMA co-primary endpoints in the phase III OPTIC (Omadacycline for Pneumonia Treatment in the Community) trial in patients with community-acquired bacterial pneumonia (CABP).